Gilead Sciences is relying on its new CAR-T therapy for multiple myeloma to succeed more than ever. The company recently reported positive results from a clinical trial, showing that 96% of patients with the disease responded to treatment and 74% achieved complete remission. This promising news comes as sales of Gilead’s existing CAR-T therapies are weakening.
Source: https://www.statnews.com/2025/12/07/gilead-arcellx-multiple-myeloma-treatment-anito-cel-promising-data-ash